Your browser doesn't support javascript.
loading
B-ALL With t(5;14)(q31;q32); IGH-IL3 Rearrangement and Eosinophilia: A Comprehensive Analysis of a Peculiar IGH-Rearranged B-ALL.
Fournier, Benjamin; Balducci, Estelle; Duployez, Nicolas; Clappier, Emmanuelle; Cuccuini, Wendy; Arfeuille, Chloé; Caye-Eude, Aurélie; Delabesse, Eric; Bottollier-Lemallaz Colomb, Elodie; Nebral, Karin; Chrétien, Marie-Lorraine; Derrieux, Coralie; Cabannes-Hamy, Aurélie; Dumezy, Florent; Etancelin, Pascaline; Fenneteau, Odile; Frayfer, Jamile; Gourmel, Antoine; Loosveld, Marie; Michel, Gérard; Nadal, Nathalie; Penther, Dominique; Tigaud, Isabelle; Fournier, Elise; Reismüller, Bettina; Attarbaschi, Andishe; Lafage-Pochitaloff, Marina; Baruchel, André.
Afiliação
  • Fournier B; Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
  • Balducci E; Hematology Laboratory, University Hospital Paul-Brousse, Assistance Publique des Hôpitaux de Paris (APHP), Villejuif, France.
  • Duployez N; Department of Hematology, University Hospital, Lille, France.
  • Clappier E; Hematology Laboratory, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
  • Cuccuini W; Hematology Laboratory, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
  • Arfeuille C; Department of Genetics, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
  • Caye-Eude A; Department of Genetics, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
  • Delabesse E; Department of Haematology, Institut Universitaire de Cancérologie de Toulouse, CHU de Toulouse, Toulouse, France.
  • Bottollier-Lemallaz Colomb E; Department of Pediatric Oncology and Hematology, University Hospital of Dijon, Dijon, France.
  • Nebral K; Children's Cancer Research Institute (CCRI), St. Anna Kinderkrebsforschung, Vienna, Austria.
  • Chrétien ML; Department of Hematology, University Hospital of Dijon, Dijon, France.
  • Derrieux C; Hematology Laboratory, Hospital Saint Faron, Meaux, France.
  • Cabannes-Hamy A; Teenagers and Young Adults Hematology Unit, University Hospital Saint-Louis, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
  • Dumezy F; Department of Hematology, University Hospital, Lille, France.
  • Etancelin P; Department of Oncology Genetics, Henri Becquerel Center, Rouen, France.
  • Fenneteau O; Hematology Laboratory, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
  • Frayfer J; Department of Hematology, Hospital Saint Faron, Meaux, France.
  • Gourmel A; Department of Pediatric Oncology, Hematology, Immunology, University Hospital of Amiens, Amiens, France.
  • Loosveld M; Hematology Laboratory, Timone Hospital, Assistance Publique-Hôpitaux de Marseille (APHM), CNRS, INSERM, Centre d'Immunologie de Marseille-Luminy (CIML), Aix Marseille University, Marseille, France.
  • Michel G; Department of Pediatric Hematology, Aix Marseille University, Marseille, France.
  • Nadal N; Laboratory of Cytogenetics, University Hospital of Dijon, Dijon, France.
  • Penther D; Department of Oncology Genetics, Henri Becquerel Center, Rouen, France.
  • Tigaud I; Department of Cytogenetics, Lyon-Sud Hospital, Lyon, France.
  • Fournier E; Department of Hematology, University Hospital, Lille, France.
  • Reismüller B; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Attarbaschi A; Department of Pediatric Hematology and Oncology, St. Anna Children's Hospital, Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Lafage-Pochitaloff M; Hematological Cytogenetics Laboratory, Timone Hospital-Assistance Publique-Hôpitaux de Marseille (AP-HM), Aix-Marseille University, Groupe Francophone de Cytogénétique Hématologique (GFCH), Marseille, France.
  • Baruchel A; Department of Pediatric Hematology and Immunology, University Hospital Robert Debré, Assistance Publique des Hôpitaux de Paris (APHP), Paris, France.
Front Oncol ; 9: 1374, 2019.
Article em En | MEDLINE | ID: mdl-31921638
ABSTRACT

Background:

B-cell acute lymphoblastic leukemia associated with t(5;14)(q31;q32); IGH-IL3 is an exceptional cause of eosinophilia. The IGH enhancer on 14q32 is juxtaposed to the IL3 gene on 5q31, leading to interleukin-3 overproduction and release of mature eosinophils in the blood. Clinical, biological and outcome data are extremely scarce in the literature. Except for eosinophilia, no relevant common feature has been highlighted in these patients. However, it has been classified as a distinct entity in the World Health Organization classification. Cases Presentation Eight patients with t(5;14)(q31;q32) treated by French or Austrian protocols were retrospectively enrolled. Array comparative genomic hybridization, multiplex ligation-dependent probe amplification or genomic PCR search for IKZF1 deletion were performed in 7. Sixteen patients found through an exhaustive search in the literature were also analyzed. For those 24 patients, median age at diagnosis is 14.3 years with a male predominance (male to female ratio = 5). Eosinophilia-related symptoms are common (neurologic in 26%, thromboembolic in 26% or pulmonary in 50%). Median white blood cells count is high (72 × 109/L) and linked to eosinophilia (median 32 × 109/L). Peripheral blasts are present at a low level or absent (median 0 × 109/L; range 0-37 × 109/L). Bone marrow morphology is marked by a low blast infiltration (median 42%). We found an IKZF1 deletion in 5 out of 7 analyzable patients Outcome data are available for 14 patients (median follow-up 28 months) 8 died and 6 are alive in complete remission. Some of these features are concordant with those seen in patients with other IGH-rearranged B-cell acute lymphoblastic leukemias young age at onset, male sex, low blast count, high incidence of IKZF1 deletion and intermediate prognosis.

Conclusion:

Based on shared epidemiological and biological features, B-cell acute lymphoblastic leukemia with t(5;14)(q31;q32) is a peculiar subset of IGH-rearranged B-cell acute lymphoblastic leukemia with an intermediate prognosis and particular clinical features related to eosinophilia.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Guideline / Prognostic_studies Idioma: En Ano de publicação: 2019 Tipo de documento: Article